The purpose of this study is to investigate whether Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer is effective and safe.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
320
80mg/m2 infusion,d1,d8 every 3 weeks
Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Department of GI Oncology, Peking University, School of Oncology
Beijing, Beijing Municipality, China
RECRUITINGProgression free survival
Time frame: 3 year
Tumor response rate
Time frame: 1 year
Disease control rate
Time frame: 1 year
Overall survival
Time frame: 5 year
adverse evens
Time frame: 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
80mg/m2, day 1 of every 3 weeks